Xiwang Pharmaceutical Co., Ltd.'s glucose raw material has passed EU GMP recertification.

Xiwang Pharmaceutical Co., Ltd. announced that its core product, glucose API, has successfully passed the EU GMP recertification. This is another significant milestone for the company following its initial certification in 2020, signifying that Xiwang Pharmaceutical's quality management system and product quality continue to meet the highest international standards, laying a solid foundation for the company to further expand into the high-end European market.

As a leading enterprise in the domestic starch sugar API industry, Xiwang Pharmaceutical has focused on the R&D and production of glucose series products for over 20 years. With an annual production capacity of 300,000 tons of glucose API, it is one of the world's largest glucose production bases. The company's glucose products cover multiple varieties, including anhydrous glucose, monohydrate glucose, and oral glucose, with purity ranging from 99.5% to 99.9%, and are widely used in pharmaceuticals, food, and chemical industries. The glucose API that passed the EU GMP recertification this time adopts internationally advanced fully enclosed production technology, achieving full-chain quality control from corn raw materials to finished products. Key quality indicators all meet or exceed European Pharmacopoeia standards.

The quality manager of Xiwang Pharmaceutical Co., Ltd. stated, "The successful EU GMP recertification is a high recognition of the product quality and production management system of Xiwang Pharmaceutical Co., Ltd. The company has always adhered to the principle of 'quality first, customer foremost,' establishing a comprehensive quality traceability system and passing ISO9001, ISO14001, ISO45001, HACCP, and GMP certifications to ensure that every batch of products meets domestic and international regulatory requirements." It is understood that Xiwang Pharmaceutical's glucose raw materials have been exported to more than 50 countries and regions worldwide, establishing a high-quality image for "Made in China" in the international market.

This successful certification not only enhances Xiwang Pharmaceutical Co., Ltd.'s position in the global pharmaceutical supply chain but also provides an important reference for the Chinese glucose raw material industry to participate in international competition, demonstrating the strong capabilities of Chinese pharmaceutical manufacturing. In the future, Xiwang Pharmaceutical will continue to increase R&D investment, optimize its product structure, develop more high-value-added glucose derivative products, and further expand its international market reach.